Latest Oxaliplatin Stories

Indian Oncologists Are Starting to Embrace Use of Targeted Agents Despite Their High Cost, According to a Report from Decision Resources WALTHAM, Mass., April 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Sanofi-Aventis' Eloxatin, Indian brand/generics (oxaliplatin) and Roche/Chugai's Xeloda, Indian brand/generics (capecitabine) will dominate the Indian colorectal cancer drug...

- Safety and Tumor Response Data from Dose-Escalation Study Presented at American Association for Cancer Research's 100th Annual Meeting 2009 - SOUTH SAN FRANCISCO, Calif. and DENVER, April 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC). Results demonstrated that...

Unmet Need for Efficacious Therapies for Treating Patients With Mutated KRAS Genes Presents Significant Opportunity for Drug Developers, According to a New Report from Decision Resources WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launches of Roche/Genentech/Chugai's Avastin and Bristol-Myers Squibb/ImClone Systems*/Merck KGaA's Erbitux will drive the colorectal...

- Incremental Data to be Presented at ASCO GI Symposia Continue to Support Picoplatin as Neuropathy-Sparing Alternative to Oxaliplatin in First-Line Colorectal Cancer Treatment - SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients with...

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comparable to a current standard treatment, FOLFOX-4 (infused 5-FU/leucovorin plus oxaliplatin) in the first-line treatment of advanced (metastatic) colorectal cancer. In the study, patients receiving XELOX...

SOUTH SAN FRANCISCO, Jan. 8 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today provided an overview of its 2009 clinical goals for development of picoplatin, its lead product candidate. Picoplatin is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. It is currently being evaluated...

NEW YORK, Dec. 19 /PRNewswire/ -- Cancer advocacy organization Gilda's Club Worldwide offers a message of hope this holiday season to the millions touched by colon cancer with a one-of-a-kind mosaic mural at its New York City headquarters. The 15X6 foot mural was created by more than 165 colon cancer survivors from around the nation as part of a new MOSAIC of Colon Cancer Survivorship program celebrating the strides that have improved colon cancer treatment. According to the American...

KRAS Biomarker Presents Potential to Personalize Colorectal Cancer Treatment Determining Who Can Benefit from Vectibix(R) THOUSAND OAKS, Calif., Dec. 16 /PRNewswire-FirstCall/ --Amgen (Nasdaq: AMGN) today announced they will discuss the clinical utility of the KRAS gene as a predictive biomarker in patients with metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food and Drug Administration's (FDA)...

Agents bind to different targets than conventional drugsA new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences. The compounds could be less harmful than current cancer treatments on the market such as cisplatin and carboplatin because they don't penetrate the cell nucleus...

Poniard Pharmaceuticals, a biopharmaceutical company, has announced positive incremental data from its randomized, controlled Phase II clinical trial of picoplatin in patients with metastatic colorectal cancer. The expanded and updated results continue to indicate that picoplatin, given once every four weeks in combination with 5-fluorouracil and leucovorin (FOLPI), is associated with less frequent and severe neurotoxicity than oxaliplatin given in combination with 5-fluorouracil and...